Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Radiotherapy, Retlirafusp Alfa, and Chemotherapy as Neoadjuvant Therapy for ESCC
NCT07682376Phase 2Active, not recruiting
- Sponsor
- Harbin Medical University
- Start
- Jun 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Harbin Medical University. Started Jun 2026; status: active, not recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07682376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07682376.